ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC50 = 0.113 µM, Ki = 0.4 nM). ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) (HY-P1923). ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers[1].
Molecular Weight:
475.55
CAS Number:
[2748800-08-8]
Formula:
C28H30FN3O3
Target:
Akt,Apoptosis,Atg8/LC3,Autophagy,Caspase,CDK,PARP
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
